HEXA
Hexarelin
A synthetic hexapeptide, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It is an agonist at the growth hormone secretagogue receptor type 1a, the ghrelin receptor. It is also reported to bind CD36, a scavenger receptor, which distinguishes it from the more selective secretagogues in this category.
No registered human study names Hexarelin as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Hexarelin. 32 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Hexarelin; the registry search is fuzzy, so every match is re-checked. None of this says whether Hexarelin works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
32
Readership
30
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
No study of Hexarelin in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Hexarelin is, and what it has been studied for
Hexarelin is classified by ChEMBL as a protein, and appears in trial registrations under EP-23905 and MF-6003.
No registered trial names Hexarelin as an intervention, so there is no condition it has been formally studied in. It does have a literature: 32 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying Hexarelin?
Papers published each year that name Hexarelin in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 7 | 0 | Yes |
| 2018 | 7 | 0 | Yes |
| 2019 | 4 | 0 | Yes |
| 2020 | 3 | 0 | Yes |
| 2021 | 7 | 0 | Yes |
| 2022 | 2 | 0 | Yes |
| 2023 | 3 | 0 | Yes |
| 2024 | 1 | 0 | Yes |
| 2025 | 1 | 0 | Yes |
| 2026 | 2 | 0 | No |
32 papers between 2017 and 2026. A paper counts when “Hexarelin” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Hexarelin
32 indexed papers name Hexarelin in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- The cardiovascular action of hexarelin
- We are ageing
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway
- The Safety and Efficacy of Growth Hormone Secretagogues
- Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation
- The CD36-PPARγ Pathway in Metabolic Disorders
- Growth hormone-releasing peptides
- Hexarelin as a test of pituitary reserve in patients with pituitary disease
Collected 2026-08-02from PubMed, phrase-matched on “Hexarelin” in title and abstract. Run the same search.
About Hexarelin
A synthetic hexapeptide, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It is an agonist at the growth hormone secretagogue receptor type 1a, the ghrelin receptor. It is also reported to bind CD36, a scavenger receptor, which distinguishes it from the more selective secretagogues in this category.
- Also known as
- Examorelin · EP-23905
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.